Skip to main content
. 2021 Jun 7;10(6):923. doi: 10.3390/antiox10060923

Table 1.

Patients’ characteristics.

Patient Group Descriptions ACS SCAS AIS Control p-Value
(n = 10) (n = 10) (n = 10) (n = 10)
Demographic and risk factors
Age 60.0 (47.0–70.0) 69.5 (65.0–79.0) 73.5 (69.0–86.0) 69.0 (51.0–77.0) 0.02 1
Sex female/male 3/7 4/6 3/7 7/3 0.22 2
Diabetes mellitus 3 7 4 2 0.12 2
Active smoking 5 4 1 2 0.19 2
Arterial hypertension 6 7 8 8 0.50 2
Dyslipidemia 2 9 3 6 0.01 2
BMI (mean ± SD) 28.07 ± 4.10 26.85 ± 4.06 30.26 ± 5.24 30.57 ± 4.49 0.21 1
Pre-admission antithrombotic treatment
Acetylsalicylic acid 2 5 3 4
Clopidogrel 0 5 1 0
Fraxiparine 0 1 0 0
DOACs 0 0 0 2
Warfarin 0 0 0 1
Pre-admission dyslipidemic treatment
Statins 2 9 3 6
Fenofibrate 0 0 0 1
Previous coronary events
Percutaneous coronary intervention 1 0 1 0
Myocardial infarction 2 1 2 0
Coronary artery bypass graft 0 0 2 0
Ischemic stroke 0 5 10 0
Peripheral artery disease 0 4 2 0
Clinical presentation
Triacylglycerols (mM) 0.95 (0.76–1.31) 1.49 (1.00–1.72) 1.10 (0.61–2.18) 0.99 (0.64–1.13) 0.08 1
Total cholesterol (mM) 4.50 (3.87–5.44) 4.52 (3.19–4.95) 4.21 (2.32–5.40) 3.85 (3.48–5.15) 0.92 1
High density lipoproteins (mM) 1.03 (0.84–1.42) 1.36 (0.96–2.07) 0.96 (0.84–1.41) 1.44 (1.03–1.90) 0.08 1
Low density lipoproteins (mM) 3.04 (2.01–3.64) 2.00 (1.53–2.82) 2.58 (0.92–3.65) 2.13 (1.62–3.06) 0.31 1
Glycosylated hemoglobin (mmol/mol) 40.5 (36.0–96.0) 50.5 (40.0–69.0) 39.0 (33.0–57.0) 39.0 (37.0–54.0) 0.13 1

ACS: acute coronary syndrome; SCAS: significant carotid artery stenosis; AIS: acute ischemic stroke; BMI: body mass index; SD: standard deviation; NA: not available. Values are given as mean ± SD, median 5–95th percentiles in parentheses. 1 Kruskal–Wallis test, 2 Chi-square.